Why is Balaxi Pharma falling/rising?

As of 18-Jul, Balaxi Pharmaceuticals Ltd is currently priced at Rs 49.01, reflecting a slight increase of 0.1 (0.2%). The stock is trading close to its 52-week low, being only 0.98% away from Rs 48.53. Despite today's performance, which has outperformed its sector by 0.49%, the stock has been under pressure, trading below its moving averages across multiple time frames. Over the past year, Balaxi Pharma has experienced a significant decline of 55.21%, with a negative return of 32.22% year-to-date. The company's fundamentals show strong long-term potential, with an average Return on Equity (ROE) of 30.97% and healthy growth in net sales and operating profit. However, the recent flat results and a 12.7% decline in profit after tax have contributed to investor concerns, leading to a substantial drop in stock performance.
In the broader market context, Balaxi Pharmaceuticals has underperformed compared to the Sensex, which has gained 5.60% year-to-date while Balaxi has lost 32.22%. The stock's recent performance is particularly concerning given the significant drop in investor participation, with delivery volume falling by 82% against the five-day average. This lack of interest, combined with the stock's long-term underperformance relative to the BSE500, suggests that investor sentiment remains weak. Overall, while the company has strong fundamentals, the recent negative trends in performance and investor engagement are contributing to the stock's struggles in the current market environment.